Aspen Neuroscience, Inc. (ASPE) shareholders
ASPENasdaqPharmaceutical PreparationsFiscal year ends December 31
$12.00−0.23 (-1.88%)
Close on Nov 17, 2026Market cap –P/E –Yield –
Ownership
Who owns Aspen Neuroscience's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
6 buys · 0 sales
Net bought $68.00M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ARCH Venture Partners X, LLC Joint filing with ARCH Venture Fund X, L.P. (12.90%), ARCH Venture Partners X, L.P. (12.90%) and 9 more | 3,754,922 | 12.90% | 13D (active) | Nov 2, 2026 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vii LLC (12.30%) | 3,589,132 | 12.30% | 13D (active) | Nov 2, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (11.20%) | 3,250,000 | 11.20% | 13G (passive) | Oct 30, 2026 |
| Gilead Sciences, Inc. | 2,879,996 | 9.90% | 13G (passive) | Oct 30, 2026 |
| Qatar Investment Authority | 1,933,330 | 6.70% | 13G (passive) | Oct 30, 2026 |
| Patrick J. Heron Joint filing with Frazier Life Sciences X, L.P. (5.80%), Fhmls X, L.P. (5.80%) and 2 more | 1,674,321 | 5.80% | 13G (passive) | Nov 2, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Faheem Hasnain | Executive Chair, Director | 384,679 | Nov 9, 2026 |
| Damien McDevitt | See Remarks, Director | 561,648 | Oct 29, 2026 |
| Dalen Meeter | Chief Financial Officer | – | Oct 29, 2026 |
| Lisa Johnson-Pratt | Chief Commercial Officer | – | Oct 29, 2026 |
| Kim Raineri | Chief Technology Officer | – | Oct 29, 2026 |
| Jeffrey Lee Boerneke | General Counsel and Secretary | – | Oct 29, 2026 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | – | Nov 4, 2026 |
| Peter A. Thompson | Director, 10% owner | 3,589,132 | Nov 4, 2026 |
| Advisors Llc Orbimed | Director, 10% owner | 3,589,132 | Nov 4, 2026 |
| Andrew Spaventa | Director | 308,076 | Nov 2, 2026 |
| Thomas O. Daniel | Director | – | Oct 29, 2026 |
| Caryn Peterson | Director | – | Oct 29, 2026 |
| Cynthia Dorothy Perettie | Director | – | Oct 29, 2026 |
| Douglas Carl Fisher | Director | – | Oct 29, 2026 |
| ARCH Venture Fund XIV, L.P. | 10% owner | – | Nov 2, 2026 |
| Paul L. Berns | 10% owner | – | Nov 2, 2026 |
| ARCH Venture Fund X Overage, L.P. | 10% owner | – | Nov 2, 2026 |
| ARCH Venture Partners X Overage, L.P. | 10% owner | – | Nov 2, 2026 |
| ARCH Venture Partners X, LLC | 10% owner | – | Nov 2, 2026 |
| Steven Gillis | 10% owner | – | Nov 2, 2026 |
| Keith Crandell | 10% owner | – | Nov 2, 2026 |
| Robert Nelsen | 10% owner | – | Nov 2, 2026 |
| Kristina Burow | 10% owner | – | Nov 2, 2026 |
| ARCH Venture Partners X, L.P. | 10% owner | – | Nov 2, 2026 |
| ARCH Venture Fund X, L.P. | 10% owner | 2,361,074 | Nov 2, 2026 |
| ARCH Venture Partners XIV, L.P. | 10% owner | 1,200,000 | Nov 2, 2026 |
| ARCH Venture Partners XIV, LLC | 10% owner | – | Nov 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Faheem Hasnain Executive Chair, Director | Nov 5, 2026 | Award | +321,672 | – | – | 348,330 |
| Peter A. Thompson Director, 10% owner | Nov 2, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 3,589,132 |
| Peter A. Thompson Director, 10% owner | Nov 2, 2026 | Conversion | +507,119 | – | – | 2,589,132 |
| Peter A. Thompson Director, 10% owner | Nov 2, 2026 | Conversion | +625,743 | – | – | 2,082,013 |
| Peter A. Thompson Director, 10% owner | Nov 2, 2026 | Conversion | +616,984 | – | – | 1,456,270 |
| Peter A. Thompson Director, 10% owner | Nov 2, 2026 | Conversion | +642,745 | – | – | 839,286 |
| Peter A. Thompson Director, 10% owner | Nov 2, 2026 | Conversion | +196,541 | – | – | 196,541 |
| Advisors Llc Orbimed Director, 10% owner | Nov 2, 2026 | Buy | +1,000,000 | $15.00 | $15.00M | 3,589,132 |
| Advisors Llc Orbimed Director, 10% owner | Nov 2, 2026 | Conversion | +507,119 | – | – | 2,589,132 |
| Advisors Llc Orbimed Director, 10% owner | Nov 2, 2026 | Conversion | +625,743 | – | – | 2,082,013 |
| Advisors Llc Orbimed Director, 10% owner | Nov 2, 2026 | Conversion | +616,984 | – | – | 1,456,270 |
| Advisors Llc Orbimed Director, 10% owner | Nov 2, 2026 | Conversion | +642,745 | – | – | 839,286 |
| Advisors Llc Orbimed Director, 10% owner | Nov 2, 2026 | Conversion | +196,541 | – | – | 196,541 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Buy | +1,200,000 | $15.00 | $18.00M | 1,200,000 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +214,355 | – | – | 1,161,074 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +295,490 | – | – | 946,719 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +286,304 | – | – | 651,229 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +298,258 | – | – | 364,925 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Buy | +66,667 | $15.00 | $1.00M | 66,667 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +259,948 | – | – | 1,393,848 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +295,490 | – | – | 1,133,900 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +286,304 | – | – | 838,410 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +298,258 | – | – | 552,106 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Conversion | +187,182 | – | – | 253,848 |
| ARCH Venture Fund X, L.P. 10% owner | Nov 2, 2026 | Buy | +66,666 | $15.00 | $999.99K | 66,666 |
| ARCH Venture Partners XIV, L.P. 10% owner | Nov 2, 2026 | Buy | +1,200,000 | $15.00 | $18.00M | 1,200,000 |
| Andrew Spaventa Director | Nov 2, 2026 | Conversion | +180,221 | – | – | 180,221 |
| Andrew Spaventa Director | Nov 2, 2026 | Conversion | +70,194 | – | – | 70,194 |
| Faheem Hasnain Executive Chair, Director | Nov 2, 2026 | Conversion | +7,120 | – | – | 7,120 |
| Faheem Hasnain Executive Chair, Director | Nov 2, 2026 | Conversion | +14,316 | – | – | 14,316 |
| Faheem Hasnain Executive Chair, Director | Nov 2, 2026 | Conversion | +14,913 | – | – | 14,913 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
See a number that looks wrong?